Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.64 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 3/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.52 |
| ▸ | PI4KA | P42356 | 1/20 | 0.51 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.51 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9828030 | 0.87 | P2RX7 (0.52) | EGFRENPP1NT5EKDRFGFR1 | |
| SCHEMBL11249255 | 0.86 | EGFR (0.46) | EGFRENPP1NT5E | |
| SCHEMBL9426463 | 0.82 | ENPP1 (0.61) | EGFRENPP1NT5EADORA2API4KA | |
| SCHEMBL11249908 | 0.81 | P2RY11 (0.44) | EGFRENPP1NT5EADORA2ALMNA | |
| SCHEMBL9369791 | 0.81 | HDAC1 (0.48) | — | |
| SCHEMBL11729464 | 0.80 | HDAC1 (0.48) | — | |
| SCHEMBL8660736 | 0.79 | PNP (0.67) | ALDH1A1LMNASMN1; SMN2POLG | |
| SCHEMBL13723744 | 0.79 | ENPP1 (0.57) | EGFRENPP1NT5EADORA2API4KA | |
| SCHEMBL11260801 | 0.78 | MEN1 (0.52) | EGFRALDH1A1LMNASMN1; SMN2POLG | |
| SCHEMBL13724155 | 0.78 | MEN1 (0.65) | EGFRENPP1NT5EADORA2API4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | ALT SOLUTIONS, INC. | 2009-08-13 | — | — | US | disclosed |
| EP-2001488-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | Alt Solutions, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007106561-A2 | PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES | ALT SOLUTIONS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203636-A1 | Prevention and Treatment of Cancer and Other Diseases | TERT, POLRMT, RNASE1 | EGFR 2253/4885ENPP1 214/4885NT5E 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.